Comment on

• Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor.

  Breitenbuecher F, Schnittger S, Grundler R, Markova B, Carius B, Brecht A, Duyster J, Haferlach T, Huber C, Fischer T. Breitenbuecher F, et al. Blood. 2009 Apr 23;113(17):4074-7. doi: 10.1182/blood-2007-11-125476. Epub 2008 May 15. Blood. 2009. PMID: 18483393
• Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML.

  Zhou J, Bi C, Janakakumara JV, Liu SC, Chng WJ, Tay KG, Poon LF, Xie Z, Palaniyandi S, Yu H, Glaser KB, Albert DH, Davidsen SK, Chen CS. Zhou J, et al. Blood. 2009 Apr 23;113(17):4052-62. doi: 10.1182/blood-2008-05-156422. Epub 2009 Jan 14. Blood. 2009. PMID: 19144991
• A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML.

  Breitenbuecher F, Markova B, Kasper S, Carius B, Stauder T, Böhmer FD, Masson K, Rönnstrand L, Huber C, Kindler T, Fischer T. Breitenbuecher F, et al. Blood. 2009 Apr 23;113(17):4063-73. doi: 10.1182/blood-2007-11-126664. Epub 2009 Jan 14. Blood. 2009. PMID: 19144992